Pseudo-UTP

One key advancement to develop so-called drugable mRNAs was the preparation of chemically modified mRNAs, by replacing standard bases by modified ones, e.g. uridine with pseudouridine. The introduction of modified nucleobases was the foundations for clinical usage of mRNAs. The half-life of the mRNA, the translation efficiency and its immunological profile is improved. N1-methyl-pseudouridine results in more efficient translation and at the same time represses innate immune responses in comparison to the unmodified mRNA.

LITERATURE

Anderson et al., Gene Ther, 2012

Green et al., J. Biol. Chem., 2012, 287 (47):39789.

Karikó et al., Mol Ther., 2012, 20 (5):984.

Warren et al., Sci Rep., 2012, 2:657.

Anderson et al., Nucleic Acids Research., 2011, 39 (21):9329.

Karikó et al., Nucleic Acids Research., 2011, 39 (21):e142.

Anderson et al., Nucleic Acids Research., 2010, 38 (17):5884.

Warren et al., Cell Stem Cell, 2010

Karikó et al., Molecular Therapy., 2008, 16 (11):1833.

Belliot et al., Journal of Virology., 2005, 79 (4):2393.

Karikó et al., Immunity., 2005, 23 (2):165.

Charette et al., IUBMB Life., 2000, 49 (5):341.

Madore et al., Eur J Biochem., 2000, 266 (3):1128.

Goldberg et al., J. Biol. Chem., 1963, 238 (5):1793.